Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash flow, and valuation.

Recursion Pharmaceuticals is trying to solve a serious problem. Even with technological improvements, the time and costs required to develop brand-new drugs have increased in recent decades. It can ...

The maker of Claude wants AI labs, including itself, to prepare for a coordinated slowdown if models begin building their own ...

Christopher Gibson, Co-Founder and CEO, announced, "beginning January 1, the amazing Najat Khan is going to take over the role of CEO, President and Director of Recursion." Gibson will transition to ...

Artificial intelligence (AI) may not be building better versions of itself yet, but Anthropic says the world is moving closer to that possibility than many people realize. In a new research paper ...

Building a model capable of RSI would require automating a range of specialist tasks currently carried out by humans. At ...

The cognitive processes driving social media use could be key to understanding social media’s impact. Here, the authors develop a computational model of real-world social media behaviour, identifying ...